Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSC...
Dr Pascale Tomasini and Dr Catherine Shu
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC ( Dr Pascale Tomasini and Dr Catherine Shu )
27 Sep 2021
ESMO 2021: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
27 Sep 2021
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally a...
Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
24 Sep 2021
Welcome to APCCC 2021
Prof Silke Gillessen and Prof Aurelius Omlin
Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal...
Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )
21 Sep 2021
Novel therapies in multiple myeloma
Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of adv...
Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC ( Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK )
19 Sep 2021
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-ne...
Prof Hope Rugo - University of California San Francisco, San Francisco, USA
KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )
19 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )
18 Sep 2021